Published in TB and Outbreaks Week, April 27th, 2004
In a recent study from the United States, the putative "[c]ost advantages of the oral route of drug therapy administration over the intravenous route" for managing CMV disease were investigated.
"The overall costs usually are lower for the oral route of administration than for the intravenous route, although the cost to the patient depends on insurance coverage," reported K.T. Somerville and coauthors at the University of Utah Hospital. "Other advantages of the oral route include greater safety and convenience, which may improve patient adherence and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week